Sudden and irreversible diabetes triggered by immune checkpoint inhibitors is set to become more common as immunotherapy becomes the standard of care in cancer therapy, endocrinologists say. Until now fulminant islet autoimmunity that presents as diabetic ketoacidosis (DKA) has been considered a rare complication of anti-PD1 cancer therapies, but the situation is likely to change ...
Be vigilant for diabetes triggered by checkpoint inhibitors
By Michael Woodhead
26 Jun 2018